Citicoline in hypoxic ischemic encephalopathy in neonates: a randomized controlled trial.

ABSTRACT:

Background

Hypoxic-ischemic encephalopathy (HIE) is one of the major complications that can lead to death or disability in neonates. We assessed the effect of citicoline as a neuroprotector in neonates with moderate and severe HIE.

Methods

This clinical trial was carried on 80 neonates with moderate to severe HIE who were not candidates for therapeutic cooling. They were subdivided randomly into two groups; citicoline treatment group which included 40 neonates who received citicoline 10 mg / kg /12 h IV for 4 weeks plus other supportive measures and the control group which included 40 neonates who were managed with placebo and the same supportive measures. All patients were evaluated for duration of mechanical ventilation (MV), need for inotropes, seizures (type, frequency,

SUBMITTER: Salamah A 

PROVIDER: S-EPMC10182621 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature